Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare ConferenceAccesswire • 01/12/26
Moderna Stock Fights Back Against Four‑Year Curse With 20% Blastoff And A Golden CrossBenzinga • 01/07/26
MRNA Stock Jumps on Global Submissions Seeking Nod for Flu VaccineZacks Investment Research • 01/06/26
Moderna reaffirms 2025-26 guidance, eyes multiple vaccine, oncology, and rare disease launchesProactive Investors • 01/05/26
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza VaccineAccesswire • 01/05/26
MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza JabZacks Investment Research • 12/19/25
Moderna secures up to $54.3 million funding for bird flu vaccine from global coalitionReuters • 12/18/25
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine CandidateAccesswire • 12/18/25
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)Accesswire • 12/15/25
Moderna 2026 Covid and RSV growth not enough to boost stock, Jefferies saysProactive Investors • 12/12/25
Moderna (MRNA) Recently Broke Out Above the 50-Day Moving AverageZacks Investment Research • 12/08/25
Moderna (MRNA) Recently Broke Out Above the 20-Day Moving AverageZacks Investment Research • 12/04/25
Moderna, Inc. (MRNA) Presents at Piper Sandler 37th Annual Healthcare Conference TranscriptSeeking Alpha • 12/02/25
Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine RulesZacks Investment Research • 12/02/25
S&P 500 Gains and Losses Today: Moderna Falls; Synopsys Stock Climbs on Nvidia PartnershipInvestopedia • 12/01/25